Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02719613 · ClinicalTrials.gov registry record · Phase 2
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
A Phase 2 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 20
- Study locations
NCT02719613: Active Phase 2 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
NCT02719613 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 67 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02719613, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Bortezomib
- DRUG Elotuzumab
Study Locations (20)
Other
- Local Institution - 0023 - Antwerp
- Local Institution - 0010 - Halifax
- Local Institution - 0035 - Athens
- Local Institution - 0036 - Budapest
California
- Local Institution - 0017 - Bakersfield
- Local Institution - 0022 - Fountain Valley
- Local Institution - 0016 - West Hollywood
Florida
- Local Institution - 0021 - Jacksonville
- Local Institution - 0042 - St. Petersburg
Arizona
- Local Institution - 0020 - Tucson
Colorado
- Local Institution - 0019 - Denver
Georgia
- Local Institution - 0009 - Atlanta
Indiana
- Local Institution - 0003 - Indianapolis
Massachusetts
- Local Institution - 0002 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2016-07-15 |
| Est. Completion | 2025-11-13 |
| Phase | Phase 2 |
What the registry record for NCT02719613 still lists
NCT02719613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT02719613 names 20 study sites across 14 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02719613 about?
NCT02719613 is a clinical study titled "Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab". The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
What is the current status of trial NCT02719613?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2016-07-15. Estimated completion is 2025-11-13.
What conditions does trial NCT02719613 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT02719613?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Bortezomib (DRUG), Elotuzumab (DRUG).
Who is sponsoring clinical trial NCT02719613?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02719613 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02719613's enrollment target sits among peer trials
67 217th of 438 higher than 221 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI